The grades of seven biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Northwest Biotherapeutics, Inc. (NWBO) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, NWBO also gets A’s. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
This week, Pharmacyclics, Inc. (PCYC) pushes up from a C to a B rating. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. At $132.99, the stock is above the 50-day moving average of $132.37. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
Acorda Therapeutics, Inc. (ACOR) earns a B this week, jumping up from last week’s grade of C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. Shares of ACOR have increased 31.2% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Investors seem to agree with the upgraded status of the stock and have pushed the stock up 5.6% over the past month. For more information, get Portfolio Grader’s complete analysis of STML stock.
Seattle Genetics, Inc. (SGEN) improves from a C to a B rating this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Investors have pushed the stock price up 17.6% over the past month. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
The rating of Amgen (AMGN) moves up this week, rising from a B to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Wall Street seems to agree with the upgrade and has propelled the stock up 8.3% over the past month. The stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
BioMarin Pharmaceutical (BMRN) is seeing ratings go up from a C last week to a B this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Wall Street has pushed the stock higher by 13.3% over the past month. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.